Patel Jai Chand, Shukla Meenakshi, Shukla Manish
Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Nebraska, NE, United States.
Department of Neurosurgery, Translational and Vascular Research Group, Penn State Milton S. Hershey Medical Center, Hershey, PA, United States.
Front Bioeng Biotechnol. 2025 Jul 30;13:1639439. doi: 10.3389/fbioe.2025.1639439. eCollection 2025.
Mesenchymal stem cells (MSCs) are emerging as a powerful tool in regenerative medicine due to their ability to differentiate into mesenchymal lineages, such as bone, cartilage, and fat, along with their low immunogenicity and strong immunomodulatory properties. Unlike traditional cell therapies that rely on engraftment, MSCs primarily function through paracrine signaling-secreting bioactive molecules like vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF-β), and exosomes. These factors contribute to tissue repair, promote angiogenesis, and modulate immune responses in damaged or inflamed tissues. Recent studies have identified mitochondrial transfer as a novel therapeutic mechanism, where MSCs donate mitochondria to injured cells, restoring their bioenergetic function. This has expanded the therapeutic potential of MSCs to include conditions such as acute respiratory distress syndrome (ARDS) and myocardial ischemia. Clinically, MSCs have shown efficacy in diseases like graft-versus-host disease (GVHD), Crohn's disease, and COVID-19. Trials such as REMODEL and REMEDY have demonstrated improved clinical outcomes, further validating MSC-based interventions. However, several challenges remain, including variability in cell potency, poor engraftment, and inconsistent results across clinical trials. Advances in genetic engineering such as CRISPR-modified MSCs and biomaterial scaffolds are being developed to enhance therapeutic efficacy and cell survival. Additionally, AI-driven platforms are being utilized to personalize MSC therapy and optimize cell selection. Innovative approaches like 3D bioprinting and scalable manufacturing are paving the way for more consistent and precise therapies. Moving forward, the integration of mechanistic insights with robust quality control and regulatory frameworks essential to translating MSC therapies from bench to bedside and ensuring their reliable application in clinical practice.
间充质干细胞(MSCs)正成为再生医学中的一种强大工具,这是因为它们能够分化为间充质谱系,如骨、软骨和脂肪,同时具有低免疫原性和强大的免疫调节特性。与依赖植入的传统细胞疗法不同,MSCs主要通过旁分泌信号发挥作用,即分泌生物活性分子,如血管内皮生长因子(VEGF)、转化生长因子-β(TGF-β)和外泌体。这些因子有助于组织修复、促进血管生成,并调节受损或发炎组织中的免疫反应。最近的研究已将线粒体转移确定为一种新的治疗机制,即MSCs将线粒体捐赠给受损细胞,恢复其生物能量功能。这扩大了MSCs的治疗潜力,使其包括急性呼吸窘迫综合征(ARDS)和心肌缺血等病症。临床上,MSCs已在移植物抗宿主病(GVHD)、克罗恩病和COVID-19等疾病中显示出疗效。REMODEL和REMEDY等试验已证明临床结果有所改善,进一步验证了基于MSCs的干预措施。然而,仍存在一些挑战,包括细胞效力的变异性、植入不佳以及临床试验结果不一致。正在开发基因工程方面的进展,如CRISPR修饰的MSCs和生物材料支架,以提高治疗效果和细胞存活率。此外,正在利用人工智能驱动的平台实现MSCs治疗的个性化并优化细胞选择。3D生物打印和可扩展制造等创新方法正在为更一致、精确的治疗铺平道路。展望未来,将机制见解与强大的质量控制和监管框架相结合对于将MSCs疗法从实验室转化到临床并确保其在临床实践中的可靠应用至关重要。